

Updated analysis of CALGB (Alliance) 100104 assessing maintenance after single autologous stem-cell transplantation: randomised, double-blind, phase 3 trial

Lancet Haematology, the
4, e431-e442

DOI: [10.1016/s2352-3026\(17\)30140-0](https://doi.org/10.1016/s2352-3026(17)30140-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Updated analysis of CALGB (Alliance) 100104. <i>Lancet Haematology</i> , 2017, 4, e404-e405.	2.2	0
2	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	0.9	10
3	The multiple myelomas "current concepts in cytogenetic classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 409-421.	12.5	203
4	FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. <i>Oncologist</i> , 2018, 23, 734-739.	1.9	33
5	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 641-648.	2.0	19
6	Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. <i>Transplantation</i> , 2018, 102, 1994-2001.	0.5	15
7	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42
8	Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. <i>Blood Advances</i> , 2018, 2, 1608-1615.	2.5	28
9	Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.3	9
10	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 751-764.	1.1	10
11	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e20-e25.	2.0	9
12	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. <i>Clinical Therapeutics</i> , 2018, 40, 1193-1202.e1.	1.1	10
13	Update on the role of lenalidomide in patients with multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 175-190.	1.1	42
14	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
15	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
16	Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs. <i>Future Oncology</i> , 2019, 15, 4045-4056.	1.1	6
17	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 889-898.	1.1	6
18	Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2258-2269.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. Current Hematologic Malignancy Reports, 2019, 14, 31-38.	1.2	15
20	Risk adapted post-transplant maintenance in multiple myeloma. Expert Review of Hematology, 2019, 12, 107-118.	1.0	7
21	Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells. Bone Marrow Transplantation, 2019, 54, 1908-1919.	1.3	7
22	Quality of life in multiple myeloma: considerations and recommendations. Expert Review of Hematology, 2019, 12, 419-424.	1.0	32
23	Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice and Research in Clinical Haematology, 2019, 32, 54-64.	0.7	12
24	Survival analysis of multiple myeloma patients after autologous stem cell transplantation. Stem Cell Investigation, 2019, 6, 42-42.	1.3	2
26	Commentary on "Costs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale. Leukemia, 2019, 33, 565-566.	3.3	2
27	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e7-e15.	2.0	16
28	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of Blood and Marrow Transplantation, 2020, 26, 44-49.	2.0	4
29	Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. Best Practice and Research in Clinical Haematology, 2020, 33, 101140.	0.7	9
30	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer, 2020, 126, 1640-1650.	2.0	28
31	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 798-804.	2.0	28
32	Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells. Bone Marrow Transplantation, 2020, 55, 987-988.	1.3	1
33	Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation. Expert Review of Hematology, 2020, 13, 1333-1347.	1.0	1
34	Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e850-e857.	0.2	1
35	Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma "A Unique Entity. American Journal of Clinical Pathology, 2020, 154, 816-827.	0.4	12
36	Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. Clinical Cancer Research, 2020, 26, 5879-5886.	3.2	3
37	Emerging agents and regimens for multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 150.	6.9	55

#	ARTICLE	IF	CITATIONS
38	The role of high-dose melphalan with autologous stem cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	1.2	23
39	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16
40	Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. <i>European Journal of Haematology</i> , 2020, 105, 434-448.	1.1	2
41	First-line therapy with bendamustine/prednisone/bortezomib: A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 105, 116-125.	1.1	5
42	Developments in consolidation and maintenance strategies in post-remission multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 351-362.	1.0	4
43	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1323-1333.	0.6	18
44	Spontaneous remission and clonal evolution in lenalidomide associated secondary AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 1724-1727.	0.6	2
45	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
46	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020, 95, 672-690.	2.0	22
47	Current Treatment Strategies for Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, 5-14.	1.4	28
48	Maintenance Strategies After Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2020, 40, 727-740.	1.2	2
49	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1414-1424.	2.0	5
50	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020, 34, 3019-3027.	3.3	17
51	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1709-1725.	0.8	12
52	Newly Diagnosed Myeloma in 2020. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e144-e158.	1.8	9
53	Advances & future prospects in newly diagnosed multiple myeloma patients. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.6	1
54	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
55	Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2549-2557.	1.1	3

#	ARTICLE	IF	CITATIONS
56	Second primary malignancies in multiple myeloma: A review. <i>Blood Reviews</i> , 2021, 46, 100757.	2.8	30
57	Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2021, 106, 40-48.	1.1	2
58	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 5.	2.8	11
59	Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects. <i>Cancers</i> , 2021, 13, 540.	1.7	14
60	Current and future perspectives of maintenance therapy in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 225-233.	0.2	1
62	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
63	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. <i>Frontiers in Immunology</i> , 2020, 11, 573156.	2.2	8
64	Post-Transplant Maintenance Treatment Options in Multiple Myeloma. <i>Oncology and Therapy</i> , 2021, 9, 69-88.	1.0	8
65	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021, 193, 245-268.	1.2	24
66	Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. <i>Drugs</i> , 2021, 81, 825-840.	4.9	6
67	Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 148-161.	1.2	4
68	Chromosome 1q21 abnormalities in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 83.	2.8	64
69	COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021034.	0.5	4
70	Future Directions in Maintenance Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2261.	1.0	8
71	Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. <i>Journal of Proteome Research</i> , 2021, 20, 3134-3149.	1.8	11
72	Maintenance Strategies for Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 231-238.	1.0	0
73	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2664-2671.	1.3	9
74	A phase I study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	2.0	15

#	ARTICLE	IF	CITATIONS
75	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	2.8	27
76	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100444.	0.7	5
77	Cellular Immunotherapy for Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 38-44.	1.0	12
78	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	2.5	21
79	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165.	2.3	113
80	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717.	2.3	138
81	Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968.	1.2	6
82	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	0.6	8
84	What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?. , 2019, , 1-16.		0
85	What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?. , 2020, , 1531-1546.		2
87	Immunotherapeutic Strategies for Multiple Myeloma. , 2020, , 75-102.		0
88	Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. <i>Clinical Hematology International</i> , 2020, 2, 59.	0.7	3
89	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 690-699.	0.8	11
90	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 1277-1284.	3.2	4
91	Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1214-1217.	0.5	2
92	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-13.	1.3	2
93	Diagnosis and Management of Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 464.	3.8	308
94	Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. <i>Cells</i> , 2022, 11, 606.	1.8	8

#	ARTICLE	IF	CITATIONS
95	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	0.6	1
96	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 803-809.	1.3	6
97	MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. <i>Blood Advances</i> , 2022, 6, 5702-5706.	2.5	3
98	Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. <i>PLoS ONE</i> , 2022, 17, e0267979.	1.1	6
99	A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-13.	1.1	3
100	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 264.e1-264.e9.	0.6	0
101	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	1
102	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	6
103	Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma. <i>BMJ Case Reports</i> , 2022, 15, e249637.	0.2	1
104	Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211123.	0.5	0
105	Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Brasileira de Hematologia, Transfusion and Cell Therapy, 2022, , .	0.1	0
106	Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 752.e1-752.e6.	0.6	3
107	Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005â€“2016. <i>Annals of Hematology</i> , 2022, 101, 2485-2495.	0.8	8
108	CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 4492.	1.7	12
109	Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis. <i>Hematology</i> , 2022, 27, 1069-1088.	0.7	2
110	Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2022, 11, 5794.	1.0	3
111	Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. <i>Lancet Haematology</i> , 2022, 9, e906-e918.	2.2	11
112	Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. <i>ESMO Open</i> , 2022, 7, 100605.	2.0	0

#	ARTICLE	IF	CITATIONS
113	Oral Therapies for Multiple Myeloma. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 139.	0.1	0
114	The first relapse in multiple myeloma: how to pick the next best thing. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 560-568.	0.9	0
115	Newly diagnosed multiple myeloma: making sense of the menu. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 539-550.	0.9	1
116	Maintenance therapy in multiple myeloma: Two is not always better than one. <i>British Journal of Haematology</i> , 2023, 201, 181-182.	1.2	1
117	The emerging therapeutic landscape of relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2023, 102, 1-11.	0.8	12
118	Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211509.	0.5	0
119	Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	5
120	Current Main Topics in Multiple Myeloma. <i>Cancers</i> , 2023, 15, 2203.	1.7	1
124	KanzerogenitÄt antineoplastischer Substanzen. <i>Springer Reference Medizin</i> , 2022, , 1-10.	0.0	0